Rockland Immunochemicals, Inc. CSO Opines "Benefits of Polyclonal Antibodies" in peer-reviewed article
Bio-Techne Corp (TECH)
Last bio-techne corp earnings: 4/30 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.bio-techne.com
Company Research
Source: PR Web
LIMERICK, Pa. (PRWEB) August 09, 2018 Rockland Immunochemicals, Inc. announced today that Dr. Carl Ascoli, Chief Science Officer at Rockland, and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed article using their combined experience of more than 50 years. The review article was published online on August 9, 2018 and will be printed in the September 2018 issue by the journal BioTechniques. The review article, entitled "The Overlooked Benefits of Polyclonal Antibodies," discusses the pros and cons of polyclonal, conventional monoclonal, and recombinant monoclonal antibodies, while presenting procedures for experimental design, the inclusion of relevant controls, and validation strategies for polyclonal antibodies. Antibodies are critical reagents most often used by life science and translational medicine researchers and are transformative tools used to diagnose and treat disease. Many 21st century medical breakthroughs were successful in par
Show less
Read more
Impact Snapshot
Event Time:
TECH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TECH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TECH alerts
High impacting Bio-Techne Corp news events
Weekly update
A roundup of the hottest topics
TECH
News
- Bio-Techne Co. (NASDAQ: TECH) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $85.00 to $82.00. They now have a "buy" rating on the stock.MarketBeat
- BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTSPR Newswire
- BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY [Yahoo! Finance]Yahoo! Finance
- BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGYPR Newswire
- Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence [Seeking Alpha]Seeking Alpha
TECH
Earnings
- 2/1/24 - Beat
TECH
Sec Filings
- 4/5/24 - Form 4
- 3/11/24 - Form 4
- 3/7/24 - Form 144
- TECH's page on the SEC website